Business Description
Celon Pharma SA
ISIN : PLCLNPH00015
Total Employee Number:
564Compare
Compare
Traded in other countries / regions
CLN.Poland8RP.Germany0RKX.UK IPO Date
2017-02-16Description
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.03 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | 0.28 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 5.42 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | -22.6 | |||||
3-Year Book Growth Rate | -10.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.01 | |||||
9-Day RSI | 36.44 | |||||
14-Day RSI | 37.92 | |||||
3-1 Month Momentum % | 0.99 | |||||
6-1 Month Momentum % | 0.49 | |||||
12-1 Month Momentum % | -14.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.98 | |||||
Quick Ratio | 0.75 | |||||
Cash Ratio | 0.02 | |||||
Days Inventory | 178.95 | |||||
Days Sales Outstanding | 105.8 | |||||
Days Payable | 148.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.8 | |||||
Shareholder Yield % | -1.2 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 66.32 | |||||
Operating Margin % | -8.74 | |||||
Net Margin % | 68 | |||||
EBITDA Margin % | 120.69 | |||||
FCF Margin % | -5.09 | |||||
OCF Margin % | 19.08 | |||||
ROE % | 26.03 | |||||
ROA % | 20.85 | |||||
ROIC % | -2.8 | |||||
3-Year ROIIC % | 66.92 | |||||
ROC (Joel Greenblatt) % | 46.5 | |||||
ROCE % | 36.26 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 9.75 | |||||
Forward PE Ratio | 132 | |||||
PE Ratio without NRI | 9.75 | |||||
Shiller PE Ratio | 94.62 | |||||
Price-to-Owner-Earnings | 11.77 | |||||
PS Ratio | 6.56 | |||||
PB Ratio | 2.02 | |||||
Price-to-Tangible-Book | 2.1 | |||||
Price-to-Operating-Cash-Flow | 35.6 | |||||
EV-to-EBIT | 7.01 | |||||
EV-to-EBITDA | 5.79 | |||||
EV-to-Revenue | 6.99 | |||||
EV-to-FCF | -137.84 | |||||
Price-to-GF-Value | 0.86 | |||||
Price-to-Projected-FCF | 5.99 | |||||
Price-to-Graham-Number | 0.95 | |||||
Earnings Yield (Greenblatt) % | 14.24 | |||||
FCF Yield % | -0.76 | |||||
Forward Rate of Return (Yacktman) % | -14.2 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Celon Pharma SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil zł) | 159.712 | ||
| EPS (TTM) (zł) | 2.03 | ||
| Beta | 0.1191 | ||
| 3-Year Sharpe Ratio | 0.24 | ||
| 3-Year Sortino Ratio | 0.65 | ||
| Volatility % | 20.14 | ||
| 14-Day RSI | 37.92 | ||
| 14-Day ATR (zł) | 0.42289 | ||
| 20-Day SMA (zł) | 20.295 | ||
| 12-1 Month Momentum % | -14.58 | ||
| 52-Week Range (zł) | 18.5 - 24.75 | ||
| Shares Outstanding (Mil) | 53.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Celon Pharma SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Celon Pharma SA Stock Events
| Event | Date | Price (zł) | ||
|---|---|---|---|---|
| No Event Data | ||||
Celon Pharma SA Frequently Asked Questions
What is Celon Pharma SA(WAR:CLN)'s stock price today?
The current price of WAR:CLN is zł19.78. The 52 week high of WAR:CLN is zł24.75 and 52 week low is zł18.50.
When is next earnings date of Celon Pharma SA(WAR:CLN)?
The next earnings date of Celon Pharma SA(WAR:CLN) is .
Does Celon Pharma SA(WAR:CLN) pay dividends? If so, how much?
Celon Pharma SA(WAR:CLN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Celon Pharma SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers